Chris Page

In the wake of the FTC’s recent transparency report on pharmacy benefit managers, we look at how reform might impact drug channel stakeholders.

Milliman health researchers discuss strategies and benefits of making sure new medical treatments are tested in patients from a range of backgrounds.